Clinical trials: Tirzepatide, active
Obesity, Menopause
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications.
- Trial name
- NCT07057310
- Testing
- semaglutide or tirzepatide, Lifestyle modification intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Drug Discontinuation, Substance Use Disorders
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation
The goal of this clinical study with research procedures is to learn how stopping and restarting tirzepatide (a medication that helps regulate blood sugar and appetite) affects brain activity, behavior, and health in adults ages…
- Conditions
- Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
- Trial name
- CLIN-GLP1 (NCT07387796)
- Testing
- Discontinuation and Reinitiation of Tirzepatide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas at Dallas
Acute Ischemic Stroke (AIS)
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
Acute ischemic stroke caused by blockage of a large artery in the brain is one of the leading causes of death and long-term disability worldwide.
- Trial name
- TOPAZ (NCT07734792)
- Testing
- Tirzepatide, Standard Medical Care (SMC)
- Where
- China
- Volunteers
- 726 people
- Sponsor
- yifang zhu
Obesity and Obesity-related Medical Conditions
Efficacy and Safety of Tirzepatide for Weight Management
The goal of this study is to learn if tirzepatide helps people manage their weight safely. It will include adults in Bangladesh who are overweight or obese, with or without type 2 diabetes.
- Trial name
- NCT06918405
- Testing
- Tirzepatide
- Where
- Bangladesh
- Volunteers
- 440 people
- Sponsor
- Chittagong Medical College
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in…
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2
- Trial name
- ADIPO-CKD (NCT07309094)
- Testing
- GLP-1 receptor agonist, SGLT2 inhibitor, Tirzepatide
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Cardenal Herrera University
Obesity; Drug
Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.
This study aims to explore how anti-obesity medications (AOMs) like semaglutide and tirzepatide affect appetite and energy intake.
- Trial name
- NCT06856928
- Testing
- Meal Challenge
- Volunteers
- 16 people
- Sponsor
- University of Colorado, Denver
Obesity and Obesity-related Medical Conditions, Obesity and Overweight
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity.
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism
- Trial name
- MAINTAIN (NCT06734312)
- Testing
- Gastric Fundal Mucosal Ablation (GFMA)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dr. Christopher McGowan
Obesity Adult Onset
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants
This study is a randomized, double-blind, placebo-controlled trial aimed at exploring the effects of LAE102 injection in combination with Tirzepatide on body composition.
- Trial name
- NCT07671391
- Testing
- LAE102 +Tirzepatide
- Volunteers
- 60 people
- Sponsor
- Shanghai Zhongshan Hospital
Tirzepatide, Frozen Embryo Transfer
Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer
To evaluate the efficacy and safety of Dual GIP/GLP-1 receptor agonist pretreatment on reproductive outcomes in obese women before frozen embryo transfer.
- Conditions
- Tirzepatide, Frozen Embryo Transfer, Obesity
- Trial name
- NCT07811895
- Testing
- Dual GIP/GLP-1 receptor agonist
- Where
- China
- Volunteers
- 1,510 people
- Sponsor
- RenJi Hospital
Atrial Fibrillation, Obesity & Overweight
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
Obese patients with atrial fibrillation (AF) have a high recurrence rate after catheter ablation, even at experienced centers. Weight reduction improves post-ablation outcomes, but lifestyle measures alone are difficult to…
- Conditions
- Atrial Fibrillation, Obesity & Overweight, Catheter Ablation
- Trial name
- TEAR-AF (NCT07715929)
- Testing
- Tirzepatide, Structured Lifestyle Intervention
- Volunteers
- 710 people
- Sponsor
- Yunlong Wang
Obesity
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy.
- Trial name
- NCT07633639
- Testing
- LSG-Semaglutide group, LSG-Mazdutide group, LSG-Tirzepatide group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- China-Japan Friendship Hospital
Atrial Fibrillation, Obesity
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
This is a single center randomized double blind controlled study of patients (BMI ≥ 27 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo.
- Trial name
- TIRO-AF (NCT06802081)
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The Cleveland Clinic
Alcohol Use Disorder (AUD), Overweight or Obese
Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)
The investigators approach is to conduct a Phase II Double-Blind randomised controlled trial with individuals with co-occurring Alcohol Use Disorder and overweight/obesity (AUD-OOB) to receive either a sub-cutaneous injection of…
- Conditions
- Alcohol Use Disorder (AUD), Overweight or Obese, Comorbidities and Coexisting Conditions
- Trial name
- NCT07292519
- Testing
- Tirzepatide, Take Control CBT Module
- Where
- Australia
- Volunteers
- 46 people
- Sponsor
- South West Sydney Local Health District
Facial Skin Aging, Facial Volume Loss
Comparing Facial Aging Between Identical Twins With 3D Imaging
Identical twins share the same genes, which makes them a powerful way to study how lifestyle and environment - rather than genetics - affect how faces age.
- Conditions
- Facial Skin Aging, Facial Volume Loss, Wrinkle Appearance
- Trial name
- NCT07760532
- Testing
- GLP-1 Receptor Agonists
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ponsky Facial Aesthetics And Plastic Surgery, Llc
Obesity
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
This study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study
- Trial name
- NCT07000955
- Testing
- Tirzepatide, IBI362
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
The purpose of this study is to compare effects of weekly SQ semaglutide 2.4mg SQ, SQ tirzepatide 10mg, and placebo administered for 24 weeks on GES measured repeatedly at baseline, 16 weeks, 24 weeks, 28 weeks, 4 weeks after…
- Trial name
- NCT06801015
- Testing
- Semaglutide, Tirzepatide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Obesity
Comparison of Body Composition Changes With Weight Loss Interventions
This study is being done to compare the effects of a newer class of weight loss medications to weight loss surgery on the body's muscle, metabolism, and side effects over time.
- Trial name
- REFORM (NCT07115069)
- Testing
- GLP-1 receptor agonist, Gastric Bypass Surgery (laparoscopic), Gastric Bypass Surgery (robotic)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt University Medical Center
Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Mild Autonomous Cortisol Secretion (MACS) is a condition in which an adrenal gland produces excess cortisol and is associated with high blood pressure, diabetes, and weight gain.
- Trial name
- NCT07573163
- Testing
- Tirzepatide, Standard medical treatment
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Alaa Sada
Obesity, Diabetes Mellitus, Type 2
Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
This is a prospective cohort study evaluating the efficacy, safety, and tolerability of tirzepatide under real-world conditions in the Paraguayan population.
- Trial name
- REAL-TIRZEPY (NCT07588438)
- Testing
- Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.)
- Where
- Paraguay
- Volunteers
- 160 people
- Sponsor
- Las Rías Medical Center
Obesity, Sarcopenia
Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals
This randomized controlled trial aims to investigate the effects of a 24-week home-based progressive resistance exercise program combined with tirzepatide treatment on skeletal muscle mass, muscle quality, and functional capacity…
- Conditions
- Obesity, Sarcopenia, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
- Trial name
- NCT07609160
- Testing
- Resistance exercise, Lifestyle recommendations
- Volunteers
- 108 people
- Sponsor
- Acibadem University